Alphatec (NASDAQ:ATEC) Upgraded by StockNews.com to Hold

Alphatec (NASDAQ:ATEC – Get Rating) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.

Several other equities analysts have also issued reports on ATEC. Morgan Stanley boosted their price target on Alphatec from $17.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, March 1st. Needham & Company LLC restated a “buy” rating and set a $18.00 price target on shares of Alphatec in a research note on Wednesday, March 1st. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Alphatec in a research note on Wednesday, March 1st. Finally, Lake Street Capital boosted their price target on Alphatec from $16.50 to $20.00 and gave the company a “buy” rating in a research note on Thursday, January 12th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Alphatec has a consensus rating of “Moderate Buy” and an average price target of $16.25.

Alphatec Trading Up 5.4 %

Alphatec stock opened at $15.07 on Monday. Alphatec has a 52 week low of $5.73 and a 52 week high of $16.34. The company has a debt-to-equity ratio of 29.74, a quick ratio of 1.11 and a current ratio of 1.84. The firm has a market capitalization of $1.67 billion, a PE ratio of -10.25 and a beta of 1.25. The business’s 50-day simple moving average is $13.73 and its 200-day simple moving average is $11.04.

Insider Transactions at Alphatec

In other Alphatec news, Director James L. L Tullis sold 50,000 shares of the company’s stock in a transaction on Friday, December 16th. The stock was sold at an average price of $10.59, for a total transaction of $529,500.00. Following the transaction, the director now owns 497,974 shares of the company’s stock, valued at approximately $5,273,544.66. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Alphatec news, Director James L. L. Tullis sold 50,000 shares of the company’s stock in a transaction on Friday, December 16th. The stock was sold at an average price of $10.59, for a total transaction of $529,500.00. Following the transaction, the director now owns 497,974 shares of the company’s stock, valued at approximately $5,273,544.66. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Patrick Miles sold 60,000 shares of the company’s stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $13.05, for a total value of $783,000.00. Following the transaction, the chief executive officer now directly owns 5,601,633 shares in the company, valued at approximately $73,101,310.65. The disclosure for this sale can be found here. Insiders have sold 721,644 shares of company stock valued at $970,162,115 in the last three months. 33.93% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Quantamental Technologies LLC lifted its holdings in Alphatec by 8.0% during the 3rd quarter. Quantamental Technologies LLC now owns 13,170 shares of the medical technology company’s stock worth $115,000 after buying an additional 980 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Alphatec by 3.1% in the 4th quarter. Legal & General Group Plc now owns 33,038 shares of the medical technology company’s stock valued at $408,000 after purchasing an additional 994 shares during the period. CIBC Private Wealth Group LLC lifted its stake in shares of Alphatec by 8.4% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 12,904 shares of the medical technology company’s stock valued at $113,000 after purchasing an additional 1,000 shares during the period. Captrust Financial Advisors lifted its stake in shares of Alphatec by 5.2% in the 2nd quarter. Captrust Financial Advisors now owns 23,712 shares of the medical technology company’s stock valued at $155,000 after purchasing an additional 1,162 shares during the period. Finally, Metropolitan Life Insurance Co NY lifted its stake in shares of Alphatec by 35.8% in the 4th quarter. Metropolitan Life Insurance Co NY now owns 4,508 shares of the medical technology company’s stock valued at $56,000 after purchasing an additional 1,188 shares during the period. Institutional investors and hedge funds own 48.59% of the company’s stock.

About Alphatec

(Get Rating)

Alphatec Holdings, Inc engages in the design, development, and marketing of spinal fusion technology products and solutions for the treatment of spinal disorders. It offers intra-operative information and neuromonitoring technologies, access systems, interbody implants, fixation systems, and various biologics offerings.